Abstract
Background: Chronic inflammatory diseases characterized by aberrant tissue remodeling and fibrosis present significant clinical challenges. Two distinct pathologies, cholestatic liver disease and endometriosis, share underlying mechanisms of inflammation-driven tissue injury despite affecting different organ systems. This review explores the molecular underpinnings of these conditions, specifically focusing on the ubiquitin-like protein FAT10 in hepatic contexts and the metastasis-suppressor Kisspeptin in endometriosis.
Methods: We conducted a comprehensive review of recent literature focusing on the pathophysiology of cholestasis, the molecular functions of FAT10, the epidemiology of endometriosis, and the role of Kisspeptin signaling.
Results: In cholestatic liver disease, bile acid accumulation triggers inflammatory cascades leading to fibrosis. Recent evidence identifies FAT10 as a critical regulator in this process, influencing the TGF-β1/Smad and Erk/Egr-1 signaling pathways, which drive hepatic stellate cell activation and carcinogenesis. Conversely, endometriosis is characterized by the invasion of endometrial tissue outside the uterus. The expression of Kisspeptins and their regulation of Matrix Metalloproteinases (MMPs) appears crucial in modulating the invasive capacity of these ectopic lesions, acting similarly to metastasis suppressors in oncology.
Conclusion: While distinct in etiology, both cholestasis and endometriosis involve complex alterations in cell migration and survival signaling. FAT10 serves as a potential biomarker and therapeutic target for liver fibrosis and malignancy, while the Kisspeptin system offers novel insights into controlling the invasive phenotype of endometriosis. Understanding these molecular drivers provides a foundation for developing targeted therapies that interrupt the progression of fibrosis and tissue invasion.
References
Jansen PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J, et al. The ascending pathophysiology of cholestatic liver disease. Hepatology. 2017; 65: 722-38.
Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. Mayo Clin Proc. 2020; 95: 2263-79.
Ge ZH, Spicer SS. Immunocytochemistry of ion transport mediators in the genital tract of female rodents. Biol Reprod. 1988; 38: 439-52.
Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014; 60: 931-40.
Wang H, Zhang J, Zhang X, Zhao N, Zhou Z, Tao L, et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfbeta1/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022; 1868: 166556.
Buchsbaum S, Bercovich B, Ciechanover A. FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination. Mol Biol Cell. 2012; 23: 225-32.
Aichem A, Sailer C, Ryu S, Catone N, Stankovic-Valentin N, Schmidtke G, et al. The ubiquitin-like modifier FAT10 interferes with SUMO activation. Nat Commun. 2019; 10: 4452.
Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014; 13: 397-406.
Zhang K, Chen L, Zhang Z, Cao J, He L, Li L. Ubiquitin-like protein FAT10: A potential cardioprotective factor and novel therapeutic target in cancer. Clin Chim Acta. 2020; 510: 802-11.
Chen X, Wu W, Jeong JH, Rokavec M, Wei R, Feng S, et al. Cytokines-activated nuclear IKKalpha-FAT10 pathway induces breast cancer tamoxifen-resistance. Sci China Life Sci. 2024; 67: 1413-26.
Wu T, Du M, Zeng L, Wang H, Li X. Increased UBD Is a Potential Diagnostic and Prognostic Biomarker in Glioma. Environ Toxicol. 2024; 39: 5250-63.
Yang Y, He R, Li D, Mu T, Kuang Z, Wang M. The pivotal role of ZNF384: driving the malignant behavior of serous ovarian cancer cells via the LIN28B/UBD axis. Cell Biol Toxicol. 2024; 40: 100.
Zhu J, Zhao J, Luo C, Zhu Z, Peng X, Zhu X, et al. FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression. Cell Death Dis. 2022; 13: 497.
Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014; 10: 261-75.
Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 3-7.
Yen CF, Kim MR, Lee CL. Epidemiologic Factors Associated with Endometriosis in East Asia. Gynecol Minim Invasive Ther. 2019; 8: 4-11.
Szyplowska M, Tarkowski R, Kulak K. The impact of endometriosis on depressive and anxiety symptoms and quality of life: a systematic review. Front Public Health. 2023; 11: 1230303.
Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, et al. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update. 2015; 21: 500-16.
Zhang M, Xu T, Tong D, Li S, Yu X, Liu B, et al. Research advances in endometriosis-related signaling pathways: A review. Biomed Pharmacother. 2023; 164: 114909.
Kleimenova T, Polyakova V, Linkova N, Drobintseva A, Medvedev D, Krasichkov A. The Expression of Kisspeptins and Matrix Metalloproteinases in Extragenital Endometriosis. Biomedicines. 2024; 12.
Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 1997; 57: 2384-7.
Hu KL, Chang HM, Zhao HC, Yu Y, Li R, Qiao J. Potential roles for the kisspeptin/kisspeptin receptor system in implantation and placentation. Hum Reprod Update. 2019; 25: 326-43.
